In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure
Atherosclerotic renovascular disease (ARVD) reduces tissue perfusion and eventually leads to loss of kidney function with limited therapeutic options. Here we describe results of Phase 1a escalating dose clinical trial of autologous mesenchymal stem cell infusion for ARVD. Thirty-nine patients with ARVD were studied on two occasions separated by three months. Autologous adipose-derived mesenchymal stem cells were infused through the renal artery in 21 patients at three different dose levels (1, 2.5 and 5.0 x 105 cells/kg) in seven patients each.
Source: Kidney International - Category: Urology & Nephrology Authors: Abdelrhman Abumoawad, Ahmed Saad, Christopher M. Ferguson, Alfonso Eirin, Sandra M. Herrmann, LaTonya J. Hickson, Busra B. Goksu, Emily Bendel, Sanjay Misra, James Glockner, Allan B. Dietz, Lilach O. Lerman, Stephen C. Textor Tags: Clinical Trial Source Type: research
More News: Clinical Trials | Nutrition | Perfusion | Stem Cell Therapy | Stem Cells | Urology & Nephrology